Patients taking febuxostat (marketed as Uloric) to treat gout will want to pay particular attention to a recent warning issued by the FDA. Last month, the agency released a preliminary alert over concerns that the medication might be responsible for an increased risk of cardiac-related events that could lead to death when compared to an existing medication that could be used as an alternative.
Takeda Pharmaceuticals makes the drug and has been under ...
continue reading...Enough plaintiffs have joined the $2.3 billion Actos settlement, that Takeda Pharmaceuticals is going to proceed with the deal, FiercePharma reports. Last month it was unclear whether the Japan-based company would be able to attract enough plaintiffs by the September 11 deadline. But according to Takeda, 96% of Actos plaintiffs joined the settlement before the deadline. If that number rises to 97%, the company will increase the ...
As reported by Bloomberg, Takeda Pharmaceutical’s proposed $2.37 billion Actos settlement may be in danger because not enough plaintiffs are signing on. The multibillion-dollar accord was reached back in April, when Takeda agreed to use the funds to settle the bulk of its 8,000 pending Actos lawsuits.
Actos is a best-selling hypoglycemic drug approved for treatment of type 2 diabetes. Takeda has been accused of ...
continue reading...Bloomberg reports that the Japanese pharmaceutical company Takeda Pharmaceuticals has offered to pay $2.2 billion to resolve lawsuits claiming it hid bladder cancer risks associated with its diabetes drug Actos. If the settlement goes through, it will constitute one of the largest ever U.S. settlements over drug or device injury. Takeda seeks to settle over 8,000 Actos lawsuits pending in U.S. federal ...
